次世代遺伝子治療薬の開発基盤研究

DOI Web Site Web Site PubMed 被引用文献1件 参考文献45件
  • 水口 裕之
    <i>国立医薬品食品衛生研究所　遺伝子細胞医薬部</i>

書誌事項

タイトル別名
  • Basic Study for Next-generation Gene Therapy Products
  • ジ セダイ イデンシ チリョウヤク ノ カイハツ キバン ケンキュウ

この論文をさがす

抄録

Successful gene therapy depends largely on vectors that can efficiently deliver the therapeutic genes into the target tissues and cells. Recombinant adenovirus (Ad) vectors continue to be the preferred vectors for gene therapy because they can easily be grown to high titers and can efficiently transfer genes into both dividing and nondividing cells. However, there are some limitations such as the time-consuming and labor-intensive procedures for vector construction, coxsackievirus-adenovirus receptor (CAR)-dependent gene transfer, immunologic side effects, lack of tissue specificity, lack of regulation of gene expression, etc. In this paper, I review our approach to the development of advanced recombinant Ad vectors. The next generation of Ad vectors have not only become promising vectors for gene therapy but also important tools for gene transfer into mammalian cells.<br>

収録刊行物

  • 薬学雑誌

    薬学雑誌 123 (9), 761-771, 2003-09-01

    公益社団法人 日本薬学会

被引用文献 (1)*注記

もっと見る

参考文献 (45)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ